Mankind Pharma Q1FY27 Revenue at ₹4,030.59 Cr, Profit at ₹574.09 Cr
Mankind Pharma reported consolidated revenue of ₹4,030.59 crore and profit after tax of ₹574.09 crore for Q1 FY27. Standalone revenue was ₹2,964.05 crore and profit after tax was ₹558.49 crore. The results were approved by the Board on July 30, 2026.
The financial results are a routine update, but the reported growth in revenue and profit can have a moderate impact on investor sentiment and stock performance.
The company reported growth in revenue and profit for the quarter compared to the previous year, indicating positive financial performance.
Mankind Pharma Limited announced its unaudited financial results for the quarter ended June 30, 2026. The company reported consolidated revenue from operations of ₹4,030.59 crore, a notable increase from ₹3,570.35 crore in the same quarter last year. Profit after tax for the period stood at ₹574.09 crore, up from ₹444.62 crore in the corresponding quarter of the previous fiscal year.
On a standalone basis, revenue from operations for the quarter was ₹2,964.05 crore, compared to ₹2,569.73 crore in the prior year's quarter. Standalone profit after tax was reported at ₹558.49 crore. The company's net worth increased to ₹16,967.03 crore as of June 30, 2026. The Board of Directors approved these results on July 30, 2026.
What to do with a filing like this
Mankind Pharma Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Mankind Pharma Limited. Read the original for the full detail.